NEW YORK (GenomeWeb News) – The Dana-Farber Cancer Institute will use cross-species genomic analysis and validation testing in a cancer drug collaboration with Merck, the Institute said today.
 
Under the agreement, Merck will provide the Center for Applied Cancer Science at Dana-Farber with up-front and research support funding and with milestone and royalty payments if a drug is approved for marketing. CACS will retain the right to develop its antibodies independently from the collaboration with Merck.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.